European Journal of Cancer
Volume 39, Issue 6 , Pages 742-747 , April 2003

An EORTC-ECSG phase I study of LU 79553 administered every 21 or 42 days in patients with solid tumours

  • A Awada

      Affiliations

    • Jules Bordet Institute, Bd de Waterloo 125, 1000 Brussels, Belgium
    • Corresponding Author InformationCorresponding author. Tel.: +32-2-541-3219; fax: +32-2-538-0858
    • ,
  • R Thödtmann

      Affiliations

    • III. Medizinische Klinik, München, Germany
    • ,
  • M.J Piccart

      Affiliations

    • Jules Bordet Institute, Bd de Waterloo 125, 1000 Brussels, Belgium
    • ,
  • J Wanders

      Affiliations

    • New Drug Development Office, Free University Hospital, PO Box 7057, 1007 MB Amsterdam, The Netherlands
    • ,
  • A.H.G.J Schrijvers

      Affiliations

    • New Drug Development Office, Free University Hospital, PO Box 7057, 1007 MB Amsterdam, The Netherlands
    • ,
  • I.-M Von Broen

      Affiliations

    • Knoll AG, Knollstrasse, 67061 Ludwigshafen, Germany
    • ,
  • A.R Hanauske

      Affiliations

    • AK St. Georg, Division of Medical Oncology, I. Dept of Medicine, Lohmühlenstrasse 5, 20099 Hamburg, Germany

Received 17 October 2002 ,Accepted 28 October 2002.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S0959-8049(02)00776-1

doi: 10.1016/S0959-8049(02)00776-1

European Journal of Cancer
Volume 39, Issue 6 , Pages 742-747 , April 2003

Article Tools

* Image Usage & Resolution